$150 Million is the total value of Exane Asset Management's 8 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| STLA | Sell | STELLANTIS N.V SHSstock | $48,078,747,000 | -40.8% | 3,893,391 | -21.4% | 32.10% | -18.3% |
| UBS | Sell | UBS GROUP AG SHSstock | $37,757,736,000 | -42.6% | 2,339,802 | -30.0% | 25.21% | -20.7% |
| VZ | Exit | VERIZON COMMUNICATIONS INC COMstock | $0 | – | -121,546 | -100.0% | -2.99% | – |
| BAC | Exit | BK OF AMERICA CORP COMstock | $0 | – | -619,565 | -100.0% | -12.35% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-07-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UBS GROUP AG SHS | 25 | Q1 2023 | 31.8% |
| T-MOBILE US INC COM | 25 | Q3 2023 | 23.9% |
| GOLDMAN SACHS GROUP INC COM | 16 | Q3 2023 | 14.3% |
| BRISTOL-MYERS SQUIBB CO COM | 15 | Q1 2020 | 9.9% |
| CITIGROUP INC COM NEW | 15 | Q4 2022 | 18.8% |
| GILEAD SCIENCES INC COM | 15 | Q2 2019 | 8.9% |
| DBV TECHNOLOGIES S A SPONSORED ADR | 13 | Q2 2019 | 1.7% |
| CYTOMX THERAPEUTICS INC COM | 13 | Q4 2020 | 1.3% |
| MICROSOFT CORP COM | 12 | Q4 2022 | 19.4% |
| TIM PARTICIPACOES S A SPONSORED ADR | 12 | Q3 2019 | 12.2% |
View Exane Asset Management's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-04-23 |
| 13F-HR | 2024-01-24 |
| 13F-HR | 2023-10-20 |
| 13F-HR | 2023-07-17 |
| 13F-HR/A | 2023-05-11 |
| 13F-HR | 2023-04-25 |
| 13F-HR | 2023-01-17 |
| 13F-HR | 2022-10-24 |
| 13F-HR | 2022-07-15 |
| 13F-HR | 2022-04-21 |
View Exane Asset Management's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.